Avenue Therapeutics (ATXI) Competitors $0.56 -0.02 (-2.60%) As of 01:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. ALZN, SBFM, APLM, CDIO, JBIO, LIAN, PLRZ, ENSC, NKGN, and PPBTShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Alzamend Neuro (ALZN), Sunshine Biopharma (SBFM), Apollomics (APLM), Cardio Diagnostics (CDIO), Jade Biosciences (JBIO), LianBio (LIAN), Polyrizon (PLRZ), Ensysce Biosciences (ENSC), NKGen Biotech (NKGN), and Purple Biotech (PPBT). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Its Competitors Alzamend Neuro Sunshine Biopharma Apollomics Cardio Diagnostics Jade Biosciences LianBio Polyrizon Ensysce Biosciences NKGen Biotech Purple Biotech Alzamend Neuro (NASDAQ:ALZN) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Is ALZN or ATXI more profitable? Alzamend Neuro's return on equity of -181.34% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A -181.34% -116.84% Avenue Therapeutics N/A -471.57%-296.50% Do analysts recommend ALZN or ATXI? Alzamend Neuro currently has a consensus price target of $45.00, suggesting a potential upside of 1,751.85%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, equities research analysts clearly believe Alzamend Neuro is more favorable than Avenue Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to ALZN or ATXI? In the previous week, Alzamend Neuro had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for Alzamend Neuro and 1 mentions for Avenue Therapeutics. Avenue Therapeutics' average media sentiment score of 1.11 beat Alzamend Neuro's score of 0.17 indicating that Avenue Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avenue Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in ALZN or ATXI? 49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 30.2% of Alzamend Neuro shares are owned by company insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, ALZN or ATXI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$4.51MN/AN/AAvenue TherapeuticsN/AN/A-$10.38M-$0.95-0.59 SummaryAlzamend Neuro beats Avenue Therapeutics on 9 of the 10 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.79M$848.51M$5.78B$9.80BDividend YieldN/A4.84%3.95%4.02%P/E Ratio0.031.1331.2626.59Price / SalesN/A26.55464.64173.43Price / CashN/A19.5637.7359.36Price / Book0.296.7310.046.68Net Income-$10.38M-$4.20M$3.27B$265.59M7 Day Performance-4.58%15.34%3.17%3.42%1 Month Performance25.11%16.63%4.34%1.09%1 Year Performance-77.75%33.32%44.12%23.84% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics2.3936 of 5 stars$0.56-2.6%N/A-77.0%$1.79MN/A0.034Positive NewsGap DownALZNAlzamend Neuro2.8765 of 5 stars$2.35-1.1%$180.00+7,546.6%-89.2%$6.82MN/A0.004SBFMSunshine Biopharma3.0404 of 5 stars$1.43-3.1%$15.00+952.6%-50.8%$6.50M$34.87M-0.013APLMApollomics0.6767 of 5 stars$5.700.0%N/A-53.6%$6.27M$1.49M0.0045Positive NewsGap DownCDIOCardio Diagnostics1.1513 of 5 stars$3.58-3.8%$60.00+1,576.0%-68.4%$6.23M$40K0.001JBIOJade Biosciences2.1653 of 5 stars$7.37-1.7%$16.00+117.1%N/A$6.19MN/A-0.2420LIANLianBioN/A$0.06flatN/A-84.4%$6.16MN/A-0.07110PLRZPolyrizonN/A$1.02-0.9%N/AN/A$6.11MN/A0.00N/AGap DownENSCEnsysce Biosciences0.8999 of 5 stars$2.05-3.8%N/A-78.5%$6.09M$5.21M-0.5110NKGNNKGen BiotechN/A$0.13-5.4%N/A-80.7%$5.96MN/A-0.03N/APPBTPurple Biotech1.8476 of 5 stars$2.23-1.8%$33.00+1,379.8%N/A$5.78MN/A-5.3120News CoverageGap Down Related Companies and Tools Related Companies Alzamend Neuro Alternatives Sunshine Biopharma Alternatives Apollomics Alternatives Cardio Diagnostics Alternatives Jade Biosciences Alternatives LianBio Alternatives Polyrizon Alternatives Ensysce Biosciences Alternatives NKGen Biotech Alternatives Purple Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access